Home/Pipeline/TAK-280

TAK-280

Metastatic Castration-Resistant Prostate Cancer

Phase 2Active, not recruiting

Key Facts

Indication
Metastatic Castration-Resistant Prostate Cancer
Phase
Phase 2
Status
Active, not recruiting
Company

About Thermo Fisher Scientific

Thermo Fisher Scientific's mission is to enable its customers to make the world healthier, cleaner, and safer by providing the scientific tools and services that accelerate innovation. The company has achieved a dominant market position through strategic acquisitions, organic innovation, and the creation of an unparalleled, integrated ecosystem for the scientific community. Its strategy revolves around leveraging its scale and breadth to drive operational excellence, investing in high-growth areas like bioproduction and precision medicine, and selectively advancing an internal pipeline of novel therapeutics. With a market capitalization exceeding $178 billion, Thermo Fisher is a foundational pillar of the global life sciences industry.

View full company profile

Other Metastatic Castration-Resistant Prostate Cancer Drugs

DrugCompanyPhase
KEYTRUDA (pembrolizumab)MerckPhase 3
MK-5684MerckPhase 3
PNT2001Lantheus HoldingsPhase 3
ARV-766ArvinasPhase 2
Bavdegalutamide (ARV-110)ArvinasPhase 2